BAM
CHRS icon

Blueshift Asset Management’s Coherus Oncology CHRS Stock Holding History

Blueshift Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,475
Closed -$251K – 725
2022
Q1 		$251K Buy
+19,475
New +$248K 0.02% 669
2021
Q2 		– Sell
-31,995
Closed -$467K – 938
2021
Q1 		$467K Buy
+31,995
New +$543K 0.05% 488
2020
Q1 		– Sell
-13,150
Closed -$237K – 270
2019
Q4 		$237K Buy
+13,150
New +$243K 0.03% 678

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Blueshift Asset Management's CHRS Position: Q2 2022 in Review

Blueshift Asset Management sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 19,475 shares — an estimated $251K sold.

Blueshift Asset Management first reported a position in CHRS in Q4 2019 and held it in 3 quarters. The position peaked at $467K in Q1 2021. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

  • Blueshift Asset Management reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 19,475 Coherus Oncology shares in Q2 2022, an estimated $251K.
  • Blueshift Asset Management first reported a position in Coherus Oncology in Q4 2019 and held it in 3 quarters.
  • Blueshift Asset Management's Coherus Oncology position peaked at $467K in Q1 2021.
  • 176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.